Spero Therapeutics grants 556,000 awards and gets USD 6.00 target for Spero Therapeutics stock

Spero Therapeutics granted 233,000 restricted stock units and 323,000 stock options to new employees on October 1, 2026, while H.C. Wainwright raised its price target from USD 5.00 to USD 6.00 on September 14, 2026. The awards and the higher target give investors two contrasting reference points for a clinical-stage biotechnology company still rebuilding its pipeline around immunology and inflammation.

Equity awards add a dilution factor

According to BioSpace on October 2, 2026, the compensation committee approved the grants under Spero's 2019 Inducement Equity Incentive Plan and Nasdaq Listing Rule 5635(c)(4). The options vest 25 percent on the first anniversary of each employee's start date, followed by 36 equal monthly installments, while the restricted stock units vest in four equal annual installments.

The combined 556,000 awards matter because they create a potential future share-supply increase rather than an immediate cash expense for the company. The vesting schedules also make retention a condition for receiving the full awards, linking the equity cost to continued employment.

Analyst target points to SP001

As Markets Insider reported on September 14, 2026, H.C. Wainwright analyst Raghuram Selvaraju lifted the target to USD 6.00 from USD 5.00 and kept a Buy rating. The firm cited the future market potential of SP001, Spero's Fc-silent anti-CD40L antibody program.

MarketBeat reported that Spero posted second-quarter 2026 earnings per share of USD -0.16 against a USD -0.17 consensus estimate, a USD 0.01 improvement versus expectations. The result offers a quantified operating comparison, but the company remains dependent on clinical progress and partnership economics rather than a broad commercial product base.

Market value remains below yearly high

Spero had a USD 68.9 million market capitalization and a USD 1.08 to USD 3.08 52-week range as of October 6, 2026. The range puts the latest primary-market reference at 61.36 percent below the yearly high, while the USD 6.00 analyst target is materially above that market reference.

Spero's investor-relations page identifies the Nasdaq Global Market as its listing venue and SPRO as its ticker, and describes SP001 as the lead program in IgG4-related disease. Spero Therapeutics also lists the company as a clinical-stage biopharmaceutical developer focused on serious immune-mediated diseases.

Next report date is November 12

wallstreetONLINE lists November 12, 2026 as Spero's next quarterly reporting date. That date should bring the next periodized test of revenue, cash use and progress in the immunology pipeline.

Spero Therapeutics had a prior close of EUR 1.05 at Lang & Schwarz for October 5, 2026, with the quote page dated October 6, 2026. The further course of trading is shown by the continuously updated real-time quote of Spero Therapeutics stock.

More news and analyses on Spero Therapeutics stock